Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Up 6.3% Today

What is Intellia Therapeutics, Inc.?

Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a clinical-stage gene editing firm focusing on CRISPR-based therapies. The stock of NTLA showed significant bullish movement today.

Why is Intellia Therapeutics, Inc. going up?

NTLA stock is up 6.3% on Feb 19, 2026 21:00

• The bullish movement in NTLA stock today is linked to the lifting of the clinical hold on the MAGNITUDE-2 study, enabling expanded enrollment and updated safety protocols.
• The scheduled conference call to discuss fourth-quarter and full-year 2025 financial results and business updates likely impacted investor confidence in the company's future.
• H.C. Wainwright's increased price target and reiterated Buy rating contributed to a positive investor sentiment towards Intellia Therapeutics.
• Investor optimism about Intellia's gene-editing platform has been bolstered by regulatory clearance and the company's safety improvement efforts, driving the bullish market movement.

NTLA Price Chart

NTLA Technical Analysis

NTLA News

to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates - Intellia Therapeutics

Intellia Therapeutics, Inc. (Nasdaq: NTLA) announced it will host a conference call on February 26, 2026, at 8 a.m. ET to discuss its fourth quarter and full-year 2025 financial results and provide business updates. Interested parties can join via webcast or teleconference, with a replay available online for approximately 90 days. The company, a clinical-stage gene editing firm, aims to revolutionize medicine with CRISPR-based therapies for unmet medical needs.

https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-hold-conference-call-discuss-fourth-4

Clinical Hold Lifted On MAGNITUDE-2 Reshapes Intellia Gene Editing Risk Profile

Regulators have lifted the clinical hold on Intellia Therapeutics' MAGNITUDE-2 study, allowing the trial to resume with updated protocols, including a larger patient enrollment target and additional risk mitigation. This development could significantly impact Intellia's clinical pipeline risk, especially for its in vivo CRISPR treatments, and may influence future pricing discussions and partnership interest. Investors will now focus on safety signals and trial execution as the program continues.

https://finance.yahoo.com/news/clinical-hold-lifted-magnitude-2-070805405.html

Clinical Hold Lift On MAGNITUDE-2 Resets Risk Reward For Intellia Investors

Regulators have lifted the clinical hold on Intellia Therapeutics' MAGNITUDE-2 study, enabling the gene editing trial to resume with expanded enrollment and updated safety protocols. This decision removes a significant regulatory hurdle for Intellia, a clinical-stage gene editing company whose stock has seen mixed performance, with a 32.7% gain year-to-date but a substantial decline over three and five years. While the lift is positive, investors should monitor trial execution, safety updates, and the company's path to profitability, as Intellia is currently unprofitable and faces competition in the gene editing space.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/clinical-hold-lift-on-magnitude-2-resets-risk-reward-for-int

Did FDA’s MAGNITUDE-2 Clearance and Safety Focus Just Reframe Intellia Therapeutics' (NTLA) Risk Profile?

The FDA lifting the clinical hold on Intellia Therapeutics' MAGNITUDE-2 study, allowing expanded enrollment with enhanced safety monitoring, is seen as reinforcing confidence in the company's gene-editing platform. This decision clears a near-term obstacle for its ATTRv-PN program and aligns with a cautious clinical framework for its broader ATTR amyloidosis strategy. While promising for potential regulatory submissions, investors are advised to remain aware of heightened regulatory and safety scrutiny regarding serious liver events in gene-editing therapies.

https://www.sahmcapital.com/news/content/did-fdas-magnitude-2-clearance-and-safety-focus-just-reframe-intellia-therapeutics-ntla-risk-profile-2026-02-15

H.C. Wainwright Boosts Intellia (NTLA) Price Target After MAGNITUDE-2 Hold Lifted

H.C. Wainwright has raised its price target for Intellia Therapeutics (NTLA) to $25 from $15 and reiterated a Buy rating. This upgrade follows the lifting of a clinical hold on the company's MAGNITUDE-2 study. The revised protocol for the study now targets approximately 60 patients, an increase from 50, to mitigate risks and improve data understanding.

https://finviz.com/news/311325/hc-wainwright-boosts-intellia-ntla-price-target-after-magnitude-2-hold-lifted

Trending Today

Oracle Corporation ($ORCL) Stock Forecast: Down 5.5% Today

Opendoor Technologies Inc. ($OPEN) Stock Forecast: Up 6.1% Today

Corning Incorporated ($GLW) Stock Forecast: Up 7.6% Today

Coinbase Global Inc. ($COIN) Stock Forecast: Up 5.2% Today

Silver ($XAG) Commodity Forecast: Up 5.4% Today

Chemours Company (The) ($CC) Stock Forecast: Down 21.2% Today

Etsy Inc. ($ETSY) Stock Forecast: Up 7.1% Today

Dow Inc. ($DOW) Stock Forecast: Down 5.9% Today

Roblox Corp ($RBLX) Stock Forecast: Down 5.1% Today

Lemonda Inc. ($LMND) Stock Forecast: Down 5.5% Today

Intellia Therapeutics, Inc. Price History

05.01.2026 - NTLA Stock was down 6.0%

• The decline in NTLA's stock value today might be due to investors selling to realize profits following a previous uptick in price.
• Despite receiving approval for its clinical trial and a raised price target, concerns about the company's long-term profitability may have shifted market sentiment.
• The market may be reacting to the company's ongoing losses despite positive regulatory news, causing uncertainty about its future financial performance.
• Investors might be wary of the continued clinical hold on the MAGNITUDE trial for ATTR-CM, which could be viewed as a risk factor affecting the stock's movement.

05.01.2026 - NTLA Stock was down 6.8%

• While the FDA lifted the clinical hold on Intellia's Phase 3 trial for hereditary transthyretin amyloidosis, the stock did not respond positively.
• Despite analysts raising price targets and institutional investors expressing optimism, the stock continued its bearish movement.
• Market reaction may have been influenced by ongoing concerns about a separate clinical hold on the cardiomyopathy study, overshadowing progress in the ATTRv-PN trial.
• Conflicting price targets provided by Baird and H.C. Wainwright possibly introduced uncertainty among investors, contributing to the stock's decline.

13.01.2026 - NTLA Stock was up 8.7%

• The FDA's decision to lift the clinical hold on Intellia Therapeutics' MAGNITUDE-2 Phase 3 trial for nexiguran ziclumeran was a significant positive driver for the stock, leading to a notable increase in share price.
• Despite this positive development, concerns about the company's profitability and high price-to-sales ratio relative to industry averages have sparked discussions about the stock's valuation and future growth prospects.
• Analysts, on average, recommend holding the stock with a price target of $18.00. Insider selling and institutional ownership changes contribute to the mixed outlook on NTLA's valuation and potential future performance.

04.01.2026 - NTLA Stock was down 5.7%

• The FDA lifting the clinical hold on Intellia's Phase 3 trial for hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) was initially seen as a positive development, but the market reacted negatively, causing a 12.6% drop in the stock price.
• Despite the regulatory hurdle being cleared, investors may be concerned about the ongoing hold on the MAGNITUDE cardiomyopathy trial, leading to uncertainty about the company's future pipeline.
• Analysts providing varied ratings and decreased price targets could also contribute to the bearish sentiment, as the market digests the implications of the FDA decision and assesses the company's overall financial health and growth prospects.

19.01.2026 - NTLA Stock was up 6.3%

• The bullish movement in NTLA stock today is linked to the lifting of the clinical hold on the MAGNITUDE-2 study, enabling expanded enrollment and updated safety protocols.
• The scheduled conference call to discuss fourth-quarter and full-year 2025 financial results and business updates likely impacted investor confidence in the company's future.
• H.C. Wainwright's increased price target and reiterated Buy rating contributed to a positive investor sentiment towards Intellia Therapeutics.
• Investor optimism about Intellia's gene-editing platform has been bolstered by regulatory clearance and the company's safety improvement efforts, driving the bullish market movement.

27.00.2026 - NTLA Stock was up 5.8%

• NTLA stock soared by 10% today in a strong bullish movement.
• A clinical hold on one of Intellia's advanced gene therapy trials for ATTRv-PN was lifted by the FDA, allowing the company to restart patient enrollment.
• The FDA's approval to resume the trial has instilled confidence in Intellia's gene editing initiatives, leading to a notable surge in the stock price.
• Investors are keenly watching for further regulatory decisions on Intellia's clinical trials, especially concerning the ATTR amyloidosis program, which is expected to impact the stock's performance in the near term.

10.01.2026 - NTLA Stock was down 5.2%

• Despite recent developments in its MAGNITUDE-2 Phase 3 trial, Intellia Therapeutics (NTLA) saw a 6.6% decline in its stock price.
• Concerns over the ongoing hold on another trial, ATTR-CM MAGNITUDE, have affected investor confidence and contributed to the stock's bearish movement.
• Analysts' decision to maintain a "Hold" rating, reduce price targets, and insider selling have further impacted the sentiment surrounding NTLA's stock.
• The company's status as currently loss-making, alongside debates on its valuation, has led to increased stock volatility and caution among investors regarding future regulatory challenges.

18.01.2026 - NTLA Stock was up 5.1%

• The surge in NTLA stock can be linked to the regulatory approval to resume the MAGNITUDE-2 study with expanded enrollment and enhanced safety protocols.
• Analysts, including H.C. Wainwright, have raised price targets and reiterated Buy ratings on NTLA, showing increased confidence in the company's gene-editing technology.
• Investors are focusing on the trial progress, safety updates, and Intellia's path to profitability amid industry competition despite regulatory advancements.
• The decision to lift the clinical hold marks a significant milestone for Intellia, potentially altering its risk profile and impacting future pricing discussions and partnership opportunities.

28.00.2026 - NTLA Stock was down 8.8%

• NTLA saw a decline in its stock value as the FDA removed the clinical hold on one of its gene therapy trials for ATTRv-PN, causing uncertainty in the market.
• The ongoing hold on the trial for ATTR-CM due to severe side effects and a patient's death added to the pessimism surrounding NTLA.
• Despite the positive development of the FDA allowing the resumption of patient enrollment in one trial, concerns about regulatory issues and safety continued to impact NTLA's stock performance.
• Investors appear cautious about potential safety implications on NTLA's future trials and its ability to handle regulatory hurdles efficiently.

03.01.2026 - NTLA Stock was down 5.1%

• Despite the FDA lifting the clinical hold on Intellia's MAGNITUDE-2 Phase 3 trial for hereditary transthyretin amyloidosis, the stock plummeted 12.6%, reflecting investor apprehension.
• Diverse analyst ratings and price forecasts for NTLA, along with some analysts lowering their targets despite strong financial performance, likely impacted the downward trend.
• The market's attention towards the trial's advancement, upcoming regulatory developments, and existing clinical, regulatory, and financial uncertainties potentially contributed to the prevailing negative market outlook towards Intellia Therapeutics.

30.00.2026 - NTLA Stock was down 7.6%

• The FDA's decision to lift the clinical hold on Intellia's Phase III trial for hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) resulted in a temporary boost in the stock price.
• However, the ongoing hold on the MAGNITUDE trial for cardiomyopathy patients, attributed to severe liver-related side effects, raised uncertainties and potential concerns among investors, contributing to the recent bearish trend.
• Despite the positive development of trial resumptions, persistent safety concerns and regulatory scrutiny surrounding Intellia's gene therapy programs likely influenced investor sentiment, leading to the bearish market activity.
• The diverse analyst ratings and the decrease in the average price target may have also impacted the downward movement, reflecting differing perspectives on the company's future despite its strong financial performance.

30.00.2026 - NTLA Stock was down 6.9%

• The FDA lifted a clinical hold on one of Intellia's late-stage gene therapy trials for hereditary transthyretin amyloidosis, allowing the company to resume patient enrollment. This news initially resulted in a 10% rise in shares.
• Despite the positive development regarding the lifted clinical hold, the bearish movement may be linked to the continued hold on another trial for ATTR-CM due to severe liver-related side effects, including a patient's death.
• Intellia's financial performance remains solid, with revenue growth and strong ratios. However, market sentiment could have been affected by uncertainties related to the paused trial and the necessity for new risk mitigation measures.
• Analysts have provided diverse ratings for Intellia Therapeutics, with some lowering price targets. This may be indicative of concerns about the regulatory obstacles facing the company, despite the promising nature of its gene-editing therapies.